Climb Bio, Inc. (CLYM)

Climb Bio Statistics

Total Valuation

Climb Bio has a market cap or net worth of $335.81 million. The enterprise value is $175.70 million.

Market Cap	335.81M
Enterprise Value	175.70M

Important Dates

The last earnings date was Thursday, March 5, 2026, before market open.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Climb Bio has 47.77 million shares outstanding. The number of shares has increased by 40.80% in one year.

Current Share Class	47.77M
Shares Outstanding	47.77M
Shares Change (YoY)	+40.80%
Shares Change (QoQ)	-0.93%
Owned by Insiders (%)	1.47%
Owned by Institutions (%)	36.34%
Float	27.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.09
P/TBV Ratio	2.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.16, with a Debt / Equity ratio of 0.00.

Current Ratio	15.16
Quick Ratio	14.47
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -32.15% and return on invested capital (ROIC) is -22.72%.

Return on Equity (ROE)	-32.15%
Return on Assets (ROA)	-22.04%
Return on Invested Capital (ROIC)	-22.72%
Return on Capital Employed (ROCE)	-42.23%
Weighted Average Cost of Capital (WACC)	2.91%
Revenue Per Employee	n/a
Profits Per Employee	-$2.06M
Employee Count	29
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +462.40% in the last 52 weeks. The beta is -0.24, so Climb Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.24
52-Week Price Change	+462.40%
50-Day Moving Average	5.47
200-Day Moving Average	2.86
Relative Strength Index (RSI)	61.58
Average Volume (20 Days)	661,957

Short Selling Information

The latest short interest is 1.75 million, so 3.67% of the outstanding shares have been sold short.

Short Interest	1.75M
Short Previous Month	1.92M
Short % of Shares Out	3.67%
Short % of Float	6.29%
Short Ratio (days to cover)	2.82

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-67.88M
Pretax Income	-59.85M
Net Income	-59.85M
EBITDA	-67.79M
EBIT	-67.88M
Earnings Per Share (EPS)	-$0.90

Balance Sheet

The company has $101.08 million in cash and $541,000 in debt, with a net cash position of $160.11 million or $3.35 per share.

Cash & Cash Equivalents	101.08M
Total Debt	541,000
Net Cash	160.11M
Net Cash Per Share	$3.35
Equity (Book Value)	160.48M
Book Value Per Share	3.36
Working Capital	98.87M

Cash Flow

In the last 12 months, operating cash flow was -$54.36 million and capital expenditures -$186,000, giving a free cash flow of -$54.54 million.

Operating Cash Flow	-54.36M
Capital Expenditures	-186,000
Free Cash Flow	-54.54M
FCF Per Share	-$1.14

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Climb Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.80%
Shareholder Yield	-40.80%
Earnings Yield	-17.82%
FCF Yield	-16.24%

Analyst Forecast

The average price target for Climb Bio is $15.29, which is 117.50% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$15.29
Price Target Difference	117.50%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	22.12%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1